CORRECTION: RadNet's DeepHealth Subsidiary Expands FDA Clearance for SmartMammo™ Solution
Portfolio Pulse from
RadNet's subsidiary, DeepHealth, has expanded FDA clearance for its SmartMammo™ solution. A correction was issued regarding the initial clearance year, which is 2021, not 2012.
November 29, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RadNet's DeepHealth subsidiary has expanded FDA clearance for its SmartMammo™ solution, correcting the initial clearance year to 2021.
The expansion of FDA clearance for SmartMammo™ is a positive development for RadNet, potentially enhancing its product offerings and market position. The correction of the clearance year to 2021 clarifies the timeline of regulatory approval, which is crucial for investor confidence.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90